Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

Next Previous
X
Search
Trial Profile

STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Faricimab (Primary) ; Ranibizumab
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms STAIRWAY
  • Sponsors Roche

    • Most Recent Events

    • 30 Oct 2018 According to a Roche media release, based on the STAIRWAY data, a global phase III programme for faricimab in neovascular age related macular degeneration (nAMD) is anticipated to commence in 2019.
    • 29 Oct 2018 Results published in a Roche Media Release.
    • 26 Oct 2018 Positive results of the study were presented as a late-breaking oral presentation during the 2018 American Academy of Ophthalmologys (AAO) Annual Meeting in Chicago, Illinois, United States, according to a Roche media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top